Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma

<div>Radiologic response to chemotherapy with both VIA and VIP per patient (<i>n</i> = 34). Only evaluable patients are shown who had imaging after 2 cycles of VIA and 2 cycles of VIP. VIA: vincristine, ifosfamide, and doxorubicin; VIP: etoposide, ifosfamide, and cisplatin.</div>

Sarcoma

fig3

Figure 3

Figure 3: Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma 

Figure 3 | Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma 